Infinity Pharmaceuticals INFI today announced updated
Phase 1 data from an ongoing study of IPI-145, its oral inhibitor of
phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with
relapsed/refractory indolent non-Hodgkin lymphoma (iNHL), a potentially
fatal hematologic malignancy (blood cancer). Data from the study showed
that IPI-145 was clinically active, with an overall response rate of 73
percent, including three complete responses, among patients receiving
IPI-145 dosed at ≤ 25 mg twice daily (BID). Data also showed that 53
percent of patients remained progression free for over one year. These
data support DYNAMO, the ongoing Phase 2 study of IPI-145 in patients
with refractory iNHL. These findings were presented today at the 55th
Annual Meeting of the American Society of Hematology (ASH).
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in